Micropapillary Urothelial Carcinoma: A Review and Update

Micropapillary urothelial carcinoma is a well-recognized subtype of urothelial carcinoma that is associated with an aggressive clinical course. Its recognition is critical for optimal management; however, strict diagnostic criteria are not always applied, resulting in interobserver variability in recognition and reporting. The genomic profiles of micropapillary urothelial carcinoma overlap with those of classic urothelial carcinoma, but show higher rates of alterations in the cell cycle regulators TP53 and RB1 and the receptor tyrosine kinase ERBB2 . Recently approved therapeutic agents targeting cell surface markers such as HER2 and NECTIN4 provide promising novel and potentially more effective therapies for micropapillary urothelial carcinoma.

Authors

Institutions

Publication Details

Journal
Advances in Anatomic Pathology
Published
2026-01-29
DOI
https://doi.org/10.1097/pap.0000000000000527
Citations
1
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
39.15
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Micropapillary Urothelial Carcinoma: A Review and Update

Cansu Yol, Merve Basar, Jie-Fu Chen, Hikmat Al-Ahmadie
1 citations
Advances in Anatomic Pathology
Bladder and Urothelial Cancer Treatments
39.15
article

Micropapillary Urothelial Carcinoma: A Review and Update

Cansu Yol, Merve Basar, Jie-Fu Chen, Hikmat Al-Ahmadie
article en
1 citations

Abstract

Micropapillary urothelial carcinoma is a well-recognized subtype of urothelial carcinoma that is associated with an aggressive clinical course. Its recognition is critical for optimal management; however, strict diagnostic criteria are not always applied, resulting in interobserver variability in recognition and reporting. The genomic profiles of micropapillary urothelial carcinoma overlap with those of classic urothelial carcinoma, but show higher rates of alterations in the cell cycle regulators TP53 and RB1 and the receptor tyrosine kinase ERBB2 . Recently approved therapeutic agents targeting cell surface markers such as HER2 and NECTIN4 provide promising novel and potentially more effective therapies for micropapillary urothelial carcinoma.

Advances in Anatomic PathologyVol. 33(2)
Memorial Sloan Kettering Cancer Center (US)
Good health and well-being
Openalex Percentile: Top 1%
Bladder and Urothelial Cancer Treatments
39.15
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.